TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18061271

Group type: EXPERIMENTAL
Intervention: Topical and intracameral anesthesia (supplementary intracameral lidocaine)
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Topical anesthesia alone
Number of subjects: 1281
Study: 17243547

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride with calcium and vitamin D3
Number of subjects: 254

Group type: COMPARATOR
Intervention: Calcium and vitamin D3
Number of subjects: 254
Study: 12777909

Group type: EXPERIMENTAL
Intervention: Murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 110
Study: 10700898

Group type: EXPERIMENTAL
Intervention: UFT oral administration for one year at 3-4 capsules daily
Number of subjects: 435

Group type: COMPARATOR
Intervention: CDDP i.p. administration of 70 mg/m2 at the time of resective surgery
Number of subjects: 435
Study: 9118155

Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DDDR pacing mode
Number of subjects: 15

Group type: COMPARATOR
Intervention: DDD pacing mode
Number of subjects: 15
Study: 8251021

Group type: EXPERIMENTAL
Intervention: Fish oil (15 ml per day containing 3.1 g of omega-3 fatty acids)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3693871

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam (2.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study: 30009424

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (R-maintenance group)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Observation group (no rituximab maintenance)
Number of subjects: 396
Study: 26687902

Group type: EXPERIMENTAL
Intervention: Escalated dose radiotherapy (54 Gy/36f/12 days to 57.6 Gy, 61.2 Gy, and 64.8 Gy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Escalated dose radiotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: CHART radiotherapy
Number of subjects: 18
Study: 26652081

Group type: EXPERIMENTAL
Intervention: Educational intervention for spouses about supportive behaviors to control premenstrual symptoms during three educational sessions.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Educational intervention for spouses about supportive behaviors to control premenstrual symptoms.
Number of subjects: 100
Study: 23001893

Group type: EXPERIMENTAL
Intervention: Concurrent palliative care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual cancer care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint modeling approach (terminal decline model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piecewise linear random intercept model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piecewise exponential model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality-adjusted life years (QALY)
Number of subjects: 0
Study: 20564593

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 U per patient)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18371200

Group type: EXPERIMENTAL
Intervention: Reporting harm in the abstract
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Reporting harm in the main text
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Statistically significant harm in the main text
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Reporting harm in the abstract when harm is reported in the main text
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Reporting harm in the abstract when statistically significant harm is reported in the main text
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Likelihood of reporting harm in the abstract when statistically significant harm is reported in the main body
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Likelihood of reporting harm in the abstract when funded by drug companies
Number of subjects: 363
Study: 16330205

Group type: EXPERIMENTAL
Intervention: HD-M-VAC
Number of subjects: 263

Group type: COMPARATOR
Intervention: M-VAC
Number of subjects: 263
Study: 12810489

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6‐ to 12‐mg/d
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 11184213

Group type: EXPERIMENTAL
Intervention: Peer-led health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adult-led health education
Number of subjects: 0
Study: 8779365

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.kg‐1 premedication
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ephedrine 0.1 mg.kg‐1
Number of subjects: 40
Study: 2022674

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.2% in silver sulfadiazine 1%
Number of subjects: 253

Group type: COMPARATOR
Intervention: Silver sulfadiazine 1% alone
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 4% during daily dressing changes
Number of subjects: 253

Group type: COMPARATOR
Intervention: Nonantibacterial soap
Number of subjects: 253
Study: 7074523

Group type: EXPERIMENTAL
Intervention: CFP (fluorouracil, cytoxan and prednisone)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CAF (fluorouracil, cytoxan and Adriamycin)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CA (cytoxan and Adriamycin)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CFP-CA (alternating combinations of CFP and CA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: CFP-CA
Number of subjects: 126

Group type: COMPARATOR
Intervention: CA
Number of subjects: 126

Group type: COMPARATOR
Intervention: Adrenalectomy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tamoxifen (after adrenalectomy)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Adrenalectomy (after tamoxifen)
Number of subjects: 126
Study: 30969332

Group type: EXPERIMENTAL
Intervention: bell on (use-tracking IS reminder)
Number of subjects: 145

Group type: COMPARATOR
Intervention: bell off (control group)
Number of subjects: 145
Study: 30451718

Group type: EXPERIMENTAL
Intervention: Patient education by a clinical pharmacist on correct patch administration
Number of subjects: 23

Group type: COMPARATOR
Intervention: Routine counseling during patient-physician consultation (Control)
Number of subjects: 23
Study: 26729157

Group type: EXPERIMENTAL
Intervention: Omega-3 Index
Number of subjects: 266
Study: 24621348

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS) - 40 billion per day for 4 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo - one bottle per day for 4 weeks
Number of subjects: 134
Study: 21575967

Group type: EXPERIMENTAL
Intervention: Testosterone plus dutasteride
Number of subjects: 53

Group type: COMPARATOR
Intervention: Testosterone only
Number of subjects: 53
Study: 19186718

Group type: EXPERIMENTAL
Intervention: Acupuncture compound anesthesia
Number of subjects: 700

Group type: COMPARATOR
Intervention: Simple Dolantin
Number of subjects: 700
Study: 16801302

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (exact dosage and duration not specified)
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Screening protocol for eligibility
Number of subjects: 1347
Study: 12766829

Group type: EXPERIMENTAL
Intervention: Estriol-containing vaginal pessary (0.5 mg estriol) twice weekly
Number of subjects: 171

Group type: COMPARATOR
Intervention: Nitrofurantoin macrocrystal (100 mg) once daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Estriol-containing vaginal pessary
Number of subjects: 171

Group type: COMPARATOR
Intervention: Nitrofurantoin macrocrystal
Number of subjects: 171
Study: 11314355

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi Purpose (SMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (PB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syntac Single Component (Syntac)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMIP
Number of subjects: 0
Study: 9109755

Group type: EXPERIMENTAL
Intervention: Transillumination measurements
Number of subjects: 479

Group type: COMPARATOR
Intervention: Histologic slide measurements
Number of subjects: 479
Study: 1498532

Group type: EXPERIMENTAL
Intervention: gu chi wan (tooth firming pills) 4 mg twice daily for 3‐6 months combined with spiramycin 0.2 four times daily for 5 days and routine periodontal treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: spiramycin 0.2 four times daily for 5 days combined with routine periodontal treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: gu chi wan (tooth firming pills)
Number of subjects: 90
Study: 3701513

Group type: EXPERIMENTAL
Intervention: Iron therapy (experimental group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group matched for mother's educational level
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iron therapy (iron-deficient not anemic group, n = 22)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group for iron-deficient not anemic group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Placebo (iron-deficient not anemic group, n = 23)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group for placebo (iron-deficient not anemic group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Behavioral rating data (iron-deficient anemic group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group for behavioral rating data
Number of subjects: 25
Study: 31243192

Group type: EXPERIMENTAL
Intervention: CSII + liraglutide
Number of subjects: 60

Group type: COMPARATOR
Intervention: CSII
Number of subjects: 60
Study: 28646940

Group type: EXPERIMENTAL
Intervention: Intradetrusor injection of botulinum toxin type A (BTX‐A) 100 U
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior tibial nerve stimulation (PTNS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intradetrusor injection of botulinum toxin type A (BTX‐A)
Number of subjects: 60
Study: 27163420

Group type: EXPERIMENTAL
Intervention: Diltiazem infusion (2.5 microgram/kg/min)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No diltiazem infusion
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Diltiazem infusion
Number of subjects: 140
Study: 23038174

Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WGB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Brown rice (BR)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Equal mixture of whole-grain barley and brown rice (BR+WGB)
Number of subjects: 28
Study: 22180525

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 0
Study: 18998205

Group type: EXPERIMENTAL
Intervention: 3-D scapulothoracic motion assessment during scaption on affected side
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI) assessment
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Assessment of pain and dysfunction levels post-surgery
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Comparison of left vs right side affected patients
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Assessment of altered movement patterns
Number of subjects: 152
Study: 16942968

Group type: EXPERIMENTAL
Intervention: Coping With Depression Course (CWDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 15093845

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac tromethamine (0.5 mg/kg, max 30 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac tromethamine
Number of subjects: 40
Study: 11252058

Group type: EXPERIMENTAL
Intervention: Continuous passive motion for 60 seconds
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1 x 60-s hold
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2 x 30-s holds
Number of subjects: 24

Group type: COMPARATOR
Intervention: 4 x 15-s holds
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0-s hold (baseline)
Number of subjects: 24
Study: 9048403

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day continued prophylaxis, N = 90
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo, N = 89
Number of subjects: 179
Study: 7880461

Group type: EXPERIMENTAL
Intervention: Cool Mint Listerine Antiseptic mouthrinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 3537545

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 80
Study: 30347780

Group type: EXPERIMENTAL
Intervention: Whole grain intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Increase in whole fruit intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Added sugar intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Saturated fat intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat intake
Number of subjects: 136
Study: 27084247

Group type: EXPERIMENTAL
Intervention: High-dose CVVHDF (80mL/kg/h)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Conventional-dose CVVHDF (40mL/kg/h)
Number of subjects: 212
Study: 25026897

Group type: EXPERIMENTAL
Intervention: Arm A: 3 cycles of epirubicin 110 mg/m2 followed by 3 cycles of paclitaxel 200 mg/m2 followed by 3 cycles of intensified CMF
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Arm B: 3 cycles of epirubicin followed by 3 cycles of CMF, then 9 weekly cycles of docetaxel 35 mg/m2
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Arm C: 9 weekly cycles of paclitaxel 80 mg/m2
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Combined Arms B and C
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Arm B
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Patients receiving trastuzumab
Number of subjects: 1001
Study: 23039143

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the bilateral subthalamic nucleus (STN) or globus pallidus internus (GPi)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy control volunteers (CTRL group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: PD control volunteers (PD-C group)
Number of subjects: 29
Study: 21250772

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating electric toothbrush
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 20
Study: 18420714

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT: 3/wk x 12 wk)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Electrical Stimulation (ES: 1 h/day x 12 wk)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard Rehabilitation (SR: 1 h/day x 12 wk)
Number of subjects: 36
Study: 16831228

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 217

Group type: COMPARATOR
Intervention: Unvaccinated GPs
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Influenza vaccination among young GPs
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Low basic antibody titre against influenza
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Presence of influenza cases in the family
Number of subjects: 217
Study: 12625310

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 microg x kg(‐1) x min(‐1))
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Lidocaine (40 mg)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: COMPARATOR
Intervention: Remifentanil vs Placebo
Number of subjects: 155

Group type: COMPARATOR
Intervention: Lidocaine vs Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Remifentanil vs Lidocaine
Number of subjects: 155
Study: 10703660

Group type: EXPERIMENTAL
Intervention: Supra-gingival oral irrigation plus routine oral hygiene (ROH) for 14 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine oral hygiene (ROH) for 14 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: No oral hygiene for 14 days
Number of subjects: 52
Study: 9169577

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1350192

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 200
Study: 3903013

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 70
Study: 29737599

Group type: EXPERIMENTAL
Intervention: Training in Positive Behavioural Support (PBS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (non-randomized)
Number of subjects: 50
Study: 26625939

Group type: EXPERIMENTAL
Intervention: Occupational therapy protocol with supervised usage of adaptive devices (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional occupational therapy (n=20)
Number of subjects: 40
Study: 24439983

Group type: EXPERIMENTAL
Intervention: epoprostenol AM
Number of subjects: 30

Group type: COMPARATOR
Intervention: epoprostenol GM
Number of subjects: 30
Study: 22369176

Group type: EXPERIMENTAL
Intervention: Active treatment containing a seaweed-derived oligosaccharide complexed with 0.1% zinc pyrrolidone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 60
Study: 20357238

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard chest physiotherapy
Number of subjects: 28
Study: 18402631

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Discontinuing mood stabilizers
Number of subjects: 26
Study: 15932569

Group type: EXPERIMENTAL
Intervention: 5 x 5 Gy irradiation (5 fractions of 5 Gy)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy, 1.8 Gy per fraction plus bolus 5‐fluorouracil and leucovorin)
Number of subjects: 305
Study: 12913705

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (no PPS)
Number of subjects: 121
Study: 10408405

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1000 mg m‐2 intravenous (i.v.) weekly for 3 weeks out of every 4 and 5‐fluorouracil (5‐FU) 600 mg m‐2 bolus i.v. weekly for 3 weeks out of every 4
Number of subjects: 54
Study: 7551201

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with high doses of Parietaria extract (cumulative dose of 105 BU)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1763422

Group type: EXPERIMENTAL
Intervention: Cognitive training for remembering names and faces (treatment duration: one month, twice weekly)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waiting list condition (control group)
Number of subjects: 14
Study: 6123089

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Valproate sodium (VPA)
Number of subjects: 59
Study: 29847188

Group type: EXPERIMENTAL
Intervention: Combined MLD and vibrotherapy treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual lymphatic drainage (MLD)
Number of subjects: 30
Study: 30522919

Group type: EXPERIMENTAL
Intervention: Pictorial representation of carotid ultrasound plus a nurse phone call to confirm understanding
Number of subjects: 3532

Group type: COMPARATOR
Intervention: Not informed (control group)
Number of subjects: 3532
Study: 30060787

Group type: COMPARATOR
Intervention: Standard parachute technique
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Diamond-shaped anastomosis technique
Number of subjects: 56
Study: 27181130

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 25127325

Group type: EXPERIMENTAL
Intervention: FS4
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FS4-p
Number of subjects: 33

Group type: COMPARATOR
Intervention: FSP
Number of subjects: 33
Study: 22415479

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: BMI ≥ 25 kg/m(2)
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Suboptimal 25OHD (<72 nmol/l)
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: 25OHD, insulin, CRP, and leptin levels as continuous variables
Number of subjects: 1087
Study: 19329013

Group type: EXPERIMENTAL
Intervention: 5 mL 2% lidocaine
Number of subjects: 56

Group type: COMPARATOR
Intervention: 5 mL normal saline (control group)
Number of subjects: 56
Study: 17584700

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) with Gaussian kernel using 9 parameters and FIR filter
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) with Gaussian kernel using 3 standard parameters and Butterworth filter
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) with Gaussian kernel using 9 parameters and Butterworth filter
Number of subjects: 376
Study: 15177835

Group type: EXPERIMENTAL
Intervention: Healthy living booklet
Number of subjects: 252

Group type: COMPARATOR
Intervention: Patient satisfaction questionnaire
Number of subjects: 252
Study: 12174106

Group type: EXPERIMENTAL
Intervention: Azathioprine 2.5 mg kg(‐1) day(‐1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 37
Study: 9400430

Group type: EXPERIMENTAL
Intervention: 1 gm. mycophenolate mofetil twice daily
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 1.5 gm. mycophenolate mofetil twice daily
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study: 7658314

Group type: EXPERIMENTAL
Intervention: 300 U/kg rhEPO three times a week
Number of subjects: 48

Group type: COMPARATOR
Intervention: 450 U/kg rhEPO two times a week
Number of subjects: 48
Study: 2468141

Group type: EXPERIMENTAL
Intervention: New algorithm for QT sensing rate responsive pacemaker
Number of subjects: 10